Brain PET in the diagnosis of Alzheimer's disease

Clinical Nuclear Medicine

Volumn 39, Issue 10, 2014, Pages e413-e426

  Marcus, Charles ^a   Mena, Esther ^a   Subramaniam, Rathan M ^b,c  

^a UNIVERSITY OF BALTIMORE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer's disease; Amyloid brain PET; Dementia; FDG brain PET

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GANTENERUMAB; MEMANTINE; PITTSBURGH COMPOUND B; TAU PROTEIN; RADIOPHARMACEUTICAL AGENT;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; BRADYCARDIA; CLINICAL FEATURE; CONFUSION; DIAGNOSTIC ACCURACY; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DIZZINESS; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; HEADACHE; HUMAN; INFERIOR PARIETAL LOBULE; MIDDLE TEMPORAL GYRUS; MILD COGNITIVE IMPAIRMENT; MUSCLE CRAMP; NAUSEA; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PARIETAL CORTEX; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PREDICTIVE VALUE; REVIEW; SLEEP DISORDER; TEMPORAL CORTEX; URINE INCONTINENCE; VOMITING; WEAKNESS; BRAIN; SCINTISCANNING;

ALZHEIMER DISEASE; BRAIN; FRONTOTEMPORAL DEMENTIA; HUMANS; LEWY BODY DISEASE; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84925340398     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000547     Document Type: Review

References (73)

1. Eschweiler GW, Leyhe T, Kloppel S, et al. New developments in the diagnosis of dementia. Dtsch Arztebl Int. 2010;107:677-683.
2. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63-75.e2.
3. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8: 131-168.
4. Bagnoli S, Piaceri I, Sorbi S, et al. Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications. Neurodegener Dis Manag. 2014;4:73-81.
5. Ghezzi L, Scarpini E, Galimberti D. Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013;7:1471-1478.
6. Subramaniam RM, Wilcox B, Aubry MC, et al. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol. 2009;53:160-169; quiz 170.
7. Dibble EH, Karantanis D, Mercier G, et al. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol. 2012;199:952-967.
8. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012;26:527-534.
9. Davison J, Mercier G, Russo G, et al. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol. 2013;200:635-640.
10. Davison JM, Subramaniam RM, Surasi DS, et al. FDG PET/CT in patients with HIV. AJR Am J Roentgenol. 2011;197:284-294.
11. Agarwal A, Chirindel A, Shah BA, et al. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol. 2013; 200:884-890.
12. Mosconi L. Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies. Clin Transl Imaging. 2013;1:217-233.
13. Kantarci K. Molecular imaging of Alzheimer's disease pathology. AJNR Am J Neuroradiol. 2014;35(6 suppl):S12YS17.
14. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
15. Sery O, Povova J, Misek I, et al. Molecular mechanisms of neuropathological changes in Alzheimer's disease: a review. Folia Neuropathol. 2013;51:1-9.
16. Fiala JC. Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol. 2007;114:551-571.
17. Esler WP, Stimson ER, Ghilardi JR, et al. In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry. 1996; 35:749-757.
18. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129:3035-3041.
19. de Souza LC, Sarazin M, Teixeira-Junior AL, et al. Biological markers of Alzheimer's disease. Arq Neuropsiquiatr. 2014;72:227-231.
20. Buchhave P, Blennow K, Zetterberg H, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One. 2009;4:e6294.
21. Martinez-Morillo E, Hansson O, Atagi Y, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol. 2014;127:633-643.
22. Kuhl DE, Metter EJ, Riege WH, et al. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1982;2:163-171.
23. Kalpouzos G, Chetelat G, Baron JC, et al. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging. 2009;30:112-124.
24. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011;26:627-645.
25. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398.
26. Davison CM, O'Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry. 2014;29:551-561.
27. Mosconi L, Andrews RD, Matthews DC. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. J Alzheimers Dis. 2013;35:509-524.
28. Murayama N, Iseki E, Fujishiro H, et al. Detection of early amnestic mild cognitive impairment without significantly objective memory impairment: a case-controlled study. Psychogeriatrics. 2010;10:62-68.
29. Yuan Y, Gu ZX,Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer's disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol. 2009;30:404-410.
30. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-1113.
31. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332-2340.
32. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer's disease. Arch Neurol. 2005;62:1728-1733.
33. Ishii K. PETapproaches for diagnosis of dementia. AJNR Am J Neuroradiol. 2013. [Epub ahead of print].
34. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510.
35. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127.
36. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J NuclMed. 2000;41:1920-1928.
37. Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365.
38. Ossenkoppele R, Tolboom N, Foster-Dingley JC, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990-1000.
39. Gilman S, Koeppe RA, Little R, et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol. 2005; 191 Suppl 1:S95-S103.
40. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638-1645.
41. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130:2616-2635.
42. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. J Neuropathol Exp Neurol. 1997; 56:1095-1097.
43. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-2844.
44. Johnson KA, Minoshima S, Bohnen NI, et al. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013;9:e106-e109.
45. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002;12:295-298.
46. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer's disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.
47. Rinne JO, Wong DF, Wolk DA, et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol. 2012;124:833-845.
48. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
49. Cselenyi Z, Jonhagen ME, Forsberg A, et al. Clinical validation of 18FAZD4694, an amyloid-beta-specific PET radioligand.J NuclMed. 2012;53:415-424.
50. Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007;48:553-561.
51. Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer's disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584-595.
52. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001;21:RC189.
53. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
54. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
55. Zhang W, Oya S, Kung MP, et al. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005; 32:799-809.
56. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-A plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
57. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for AA imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39:983-989.
58. Hatashita S, Yamasaki H, Suzuki Y, et al. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:290-300.
59. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398-1403.
60. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-1645.
61. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856-2866.
62. Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27:4-15.
63. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
64. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer's disease treated with gantenerumab. Arch Neurol. 2012;69:198-207.
65. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer's disease. Neurology. 2006;67:446-452.
66. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001; 17:101-118.
67. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000;15:93-101.
68. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665-680.
69. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of AA and cognition in aging and Alzheimer's disease. Ann Neurol. 2011;69:181-192.
70. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67:122-131.
71. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord; 27:965-973.
72. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229-234.
73. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol. 2008; 63:377-387.